(Q39189050)

English

Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells

scientific article published on 3 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells (English)

1 reference

Europe PubMed Central

9 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Motoki Watanabe

1

1 reference

Europe PubMed Central

9 September 2017

Yoshihiro Sowa

2

1 reference

Europe PubMed Central

9 September 2017

Mayumi Yogosawa

3

1 reference

Europe PubMed Central

9 September 2017

Toshiyuki Sakai

4

1 reference

Europe PubMed Central

9 September 2017

publication date

3 April 2013

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

104

1 reference

Europe PubMed Central

9 September 2017

6

1 reference

Europe PubMed Central

9 September 2017

687-693

1 reference

Europe PubMed Central

9 September 2017

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Clinical relevance of biochemical modulation of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Thymidylate synthase as an oncogene?

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FCAS.12139

21 January 2018

p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploiting cancer cell cycling for selective protection of normal cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promises from trametinib in RAF active tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thymidylate synthase as a predictor of response.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysocellin, a metabolite of the novel drug 'alopestatin', induces G1 arrest and prevents cytotoxicity induced by etoposide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protection by cycloheximide against cytotoxicity induced by vincristine, colchicine, or delta 12-prostaglandin J2 on human osteosarcoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23438367

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/CAS.12139

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39189050&oldid=1812142404"